Description: TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Home Page: tnfpharma.com
855 N. Wolfe Street
Baltimore,
MD
21205
United States
Phone:
856 848 8698
Officers
| Name | Title |
|---|---|
| Mr. Ian Rhodes CPA | Interim Chief Financial Officer |
| Dr. Mitchell Glass M.D. | President, Chief Medical Officer & Director |
| Robert Schatz | Investor Relations Officer |
| Dr. Jenna Brager M.S., Ph.D., R.N. | Executive Vice President of Drug Development |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4357 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-01-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |